Top 5 Global Biotechnology Company Adopts Pharsight's Groundbreaking
MOUNTAIN VIEW, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software and strategic services for optimizing clinical drug development, today announced that a top five global biotechnology company has purchased WinNonlin AutoPilot. This sale marks Pharsight's third new customer win since the release of WinNonlin Autopilot in June of this year.
WinNonlin AutoPilot is configurable software that customers use to automate common or repetitive tasks during clinical pharmacokinetic (PK) analysis and to create report-ready tables and graphs. Using WinNonlin AutoPilot, companies can vastly increase their productivity while improving the quality and consistency of analyses and reports. WinNonlin AutoPilot operates with Pharsight's enterprise PK data management system, Pharsight Knowledgebase Server(TM) (PKS(TM)), and can also be used independently of PKS.
"This purchase illustrates our clients' growing interest in new, innovative tools that yield more productive, regulatory-compliant PK workflows," said Shawn O'Connor, president, chief executive officer and chairman of Pharsight. "Using AutoPilot the client can configure the PK analyses mandated by the Food and Drug Administration for any new drug submission, including business rules and formats. The potential productivity gains from automating this work are large, with the ability to reduce the labor required to generate these outputs by 80%. We believe clients will continue to invest in our market-leading software products because they offer a tangible return on investment as well as a proven pathway to more efficient drug development."
About WinNonlin AutoPilot
WinNonlin AutoPilot orchestrates PK analyses by selecting input data from a user's local file system or PKS, and then directs WinNonlin(R) to perform analyses and produce report-quality tables, figures, and text output (e.g., in Microsoft (R) Excel, SigmaPlot(R), and Microsoft(R) Word) for regulatory submissions and interim reports. Formatted PK analyses outputs must reflect the requirements and SOPs of each research organization, and WinNonlin AutoPilot provides a user-interface that allows extensive configuration of formatting and business rules to enable clear communication of standards and immediate use across the organization. PK analyses that can be automated include noncompartmental analysis for different study designs and inferential statistics (e.g., bioequivalence testing), as well as comparisons between analytes, dose routes or other conditions.
Used in conjunction with PKS and PKS Reporter(TM), WinNonlin AutoPilot provides standardized, regulatory-compliant, secure and automatic generation of routine analyses and reports. Used independently of PKS and PKS Reporter, WinNonlin AutoPilot can provide significant return on investment through productivity gains and quality improvements in PK analysis and reporting.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products. Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Forward Looking Statements
The statements in this press release related to the design and performance of the Pharsight WinNonlin AutoPilot product are forward looking statements. Forward-looking statements are inherently speculative, and actual results may differ materially from Pharsight's expectations due to a variety of factors, including: changes in FDA regulations may affect the demand for WinNonlin AutoPilot; and customers may not perceive the benefits of the product to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company's most recent Form 10-Q filed with the Securities and Exchange Commission on November 9, 2007. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.
Registered Trademarks and Trademarks
Pharsight, WinNonlin, WinNonlin AutoPilot, Pharsight Knowledgebase Server, PKS, and PKS Reporter are registered trademarks or trademarks of Pharsight Corporation. All other brand or product names mentioned in this document are trademarks or registered trademarks of their respective companies or organizations.
|SOURCE Pharsight Corporation|
Copyright©2007 PR Newswire.
All rights reserved